Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grass pollen allergy immunotherapy - Stallergenes Greer plc

Drug Profile

Grass pollen allergy immunotherapy - Stallergenes Greer plc

Alternative Names: 300 IR; 300 IR grass pollen allergen extract - Stallergenes; 300 IR SLIT; Five-grass pollen immunotherapy - Stallergenes; Oralair; Oralair Grasses

Latest Information Update: 16 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stallergenes SA
  • Developer Endo International; Stallergenes Greer plc
  • Class Allergens; Antiallergics; Plant allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 14 Nov 2018 The US FDA approves the extension of indication for grass pollen allergy immunotherapy to treat patients aged five to nine years with grass pollen-induced allergic rhinitis
  • 31 May 2017 No recent reports on development identified - Registered for Seasonal allergic rhinitis in Argentina (Sublingual)
  • 03 Mar 2017 Adverse events data from the phase III VO53.06 trial in Seasonal allergic rhinitis presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top